Clinical Trial Update: Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants [Phase 2]

View source ↗

Summary

Phase 2 trial by Inventprise evaluating safety and immunogenicity of IVT PCV-25 in healthy infants. The study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease

Drugs mentioned

• IVT PCV-25 (Pneumococcal conjugate vaccine, 25-valent)

Snippet

Sponsor: Inventprise Inc. | Conditions: Pneumococcal Disease, Invasive | Phase 2 | Status: ACTIVE_NOT_RECRUITING